yvandenbroek
/
sprookjes
/
Login
Register
TriplyDB
sprookjes
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
2
Q35528797-E0D3A5A6-2FDC-468C-BAC3-9A2944F09911
Q35528797-E0D3A5A6-2FDC-468C-BAC3-9A2944F09911
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35528797-E0D3A5A6-2FDC-468C-BAC3-9A2944F09911
Short commentary on empagliflozin and its potential clinical impact
P2860
Q35528797-E0D3A5A6-2FDC-468C-BAC3-9A2944F09911
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35528797-E0D3A5A6-2FDC-468C-BAC3-9A2944F09911
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
502c7850572ed135cc87a7b6baf67775cfed1da4
P2860
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.